Blueprint Medicines Email Format

Biotechnology Research
501-1,000 employees
Cambridge, MA, USA

Blueprint Medicines is a global biopharmaceutical company developing life-changing medicines for allergy, inflammation, oncology, and hematology conditions with two approved therapies in the U.S. and Europe.

Find contacts at Blueprint Medicines

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

firstinitiallast@blueprintmedicines.com

Company Overview

Industry
Biotechnology Research
Founded
2011
Headquarters
Cambridge, MA, USA
Revenue
$500M-$1B
FUNDING Stage
Public
Key Executives
Ariel Hurley (Head of Finance)

Tech Stack

Veeva Vault

CRM

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Blueprint Medicines?

Blueprint Medicines uses the firstinitiallast format on blueprintmedicines.com, so Jane Smith would be jsmith@blueprintmedicines.com.

What approved medicines does Blueprint Medicines currently market for systemic mastocytosis?

Blueprint Medicines markets AYVAKIT (avapritinib) in the U.S. and AYVAKYT in Europe for systemic mastocytosis, including indolent systemic mastocytosis (ISM) and advanced forms. Avapritinib targets the KIT D816V mutation present in roughly 95 percent of systemic mastocytosis cases.

Who is the CEO of Blueprint Medicines?

Kate Haviland has served as Chief Executive Officer of Blueprint Medicines since April 2022, succeeding Jeff Albers who moved into the role of Executive Chairman at that time.

Does Blueprint Medicines have a partnership for commercializing avapritinib in Greater China?

Blueprint Medicines entered into an exclusive collaboration and license agreement with CStone Pharmaceuticals in June 2018, giving CStone rights to develop and commercialize avapritinib and certain other clinical-stage candidates in Mainland China, Hong Kong, and Macau.

How can I find the right Blueprint Medicines contact or verify a Blueprint Medicines email address for outreach?

Blueprint Medicines follows a first-initial-last-name format at blueprintmedicines.com, so you can construct addresses directly. Tools like Clay can also help you verify or enrich Blueprint Medicines contact details when building a targeted outreach list.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles